Robert W. Baird lowered shares of Leap Therapeutics (NASDAQ:LPTX – Free Report) from an outperform rating to a neutral rating in a research note published on Wednesday morning, MarketBeat Ratings reports. The firm currently has $1.25 target price on the stock, down from their previous target price of $9.00.
Separately, HC Wainwright restated a “buy” rating and set a $5.50 price objective on shares of Leap Therapeutics in a report on Thursday, January 16th.
View Our Latest Analysis on LPTX
Leap Therapeutics Price Performance
Hedge Funds Weigh In On Leap Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Valence8 US LP purchased a new stake in Leap Therapeutics during the 3rd quarter valued at about $48,000. HighTower Advisors LLC purchased a new stake in Leap Therapeutics in the third quarter valued at approximately $65,000. HB Wealth Management LLC increased its holdings in Leap Therapeutics by 103.2% in the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock worth $150,000 after buying an additional 26,150 shares during the period. Key Client Fiduciary Advisors LLC raised its position in Leap Therapeutics by 13.0% during the 3rd quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock worth $827,000 after buying an additional 37,067 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Leap Therapeutics by 18.0% during the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock valued at $847,000 after acquiring an additional 50,194 shares during the period. Hedge funds and other institutional investors own 30.46% of the company’s stock.
About Leap Therapeutics
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.
Featured Stories
- Five stocks we like better than Leap Therapeutics
- Why Invest in High-Yield Dividend Stocks?
- Coinbase Gains Momentum on App Store—What It Means for the Stock
- What Is WallStreetBets and What Stocks Are They Targeting?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Stock Analyst Ratings and Canadian Analyst Ratings
- 3 Steel Stocks Soaring After Tariff Announcements
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.